Gloucester, United Kingdom
Gloucester, United Kingdom

Time filter

Source Type

Patent
Renishaw | Date: 2015-04-23

A machine tool is provided with a toolsetting probe mounted on a bed or table, and a workpiece-sensing probe which can be mounted in a movable spindle. Both probes are calibrated by using them to make measurements against each other. The arbitrary length of the workpiece-sensing probe is used to calibrate the toolsetting probe, rather than using a pre-calibrated artefact of known length mounted in the spindle. A stylus disc of the toolsetting probe has a pre-calibrated size or dimension, and the workpiece-sensing probe is calibrated with respect to that. This obviates the need for skilful manual calibration procedures using pre-calibrated artefacts and manual measurement tools.


Patent
Renishaw | Date: 2017-02-08

A method of measuring a slot using a contact probe having a stylus tip mounted on a positioning apparatus, comprising positioning the stylus tip such that it is in contact with the edges that define the mouth of the slot.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: FOF-13-2016 | Award Amount: 4.04M | Year: 2016

The ENCOMPASS project principally aims to create a fully digital integrated design decision support (IDDS) system to cover the whole manufacturing chain for a laser powder bed fusion (L-PBF) process encompassing all individual processes within in. The ENCOMPASS concept takes a comprehensive view of the L-PBF process chain through synergising and optimising the key stages. The integration at digital level enables numerous synergies between the steps in the process chain and in addition, the steps themselves are being optimised to improve the capability and efficiency of the overall manufacturing chain. ENCOMPASS addresses the three key steps in the process chain: component design, build process, and post-build process steps (post-processing and inspection). The links between these stages are being addressed by the following five interrelations: 1. Between the design process and both the build and post-build processes in terms of manufacturing constraints / considerations to optimise overall component design 2. Between the design process and build process component-specific L-PBF scanning strategies and parameters to optimise processing and reduce downstream processing 3. Between the design process and the build and post-build processes in terms of adding targeted feature quality tracking to the continuous quality monitoring throughout the process chain 4. Between the build and post-build processes by using build specific processing strategies and adaptation based on actual quality monitoring data (for inspection and post-processing) 5. Between all stages and the data management system with the integrated design decision support (IDDS) system By considering the entire AM process chain, rather than the AM machine in isolation, ENCOMPASS will integrate process decision making tools and produce substantial increases in AM productivity, with clear reductions in change over times and re-design, along with increased right-first time, leading to overall reductions in production costs, materials wastage, and over-processing. This will lead to higher economic and environmental sustainability of manufacturing, and re-inforce the EUs position in industrial leadership in laser based AM.


Grant
Agency: Cordis | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2014-ETN | Award Amount: 3.36M | Year: 2015

Enabling Excellence offers integral R&D training at PhD level around one of the most active and exciting topics at the forefront of nanoscience and nanotechnology, graphene-based nanostructures and materials. We propose a training experience built on three interrelated pillars, namely COMPREHENSION AND CONTROL, COMMERCE, and COMMUNICATION. *Comprehension & Control* covers fundamental knowledge of the nano-objects, the development of functionalities and processing into macroscopic advanced materials and devices, accompanied by a broad set of characterization techniques, to understand the interrelation between local and global properties and the requirements for functional end products. *Commerce* aims at market-ready graphene-based materials and commercial local probe Raman/AFM systems for routine quality control of graphene products. This is accompanied by innovative measures for start-up development and pitching to venture capitalists. *Communication* is the unique keystone in Enabling Excellence. The project is a novel experiment to find how best to develop the communication skills in our ESRs, creating optimum conditions under which they are best able to flourish. The results will serve as a model adaptable to European training and research at all levels. Enabling Excellence is formed by five partners from academic institutions and four private companies specialized in the above mentioned fields spanning TRL1-9. They offer a common and highly complementary modular structured training programme. During 468 ESR months we will address the need in Europe for nanocarbon specialists, training a new generation of highly skilled interdisciplinary clear thinking researchers. We will develop in these young people creativity, confidence and the ability to communicate with the most eminent scientists, technologists and business people. Enabling Excellence will equip them with the tools and self-belief necessary to maximize their potential in their future careers.


Grant
Agency: Cordis | Branch: H2020 | Program: RIA | Phase: ICT-24-2015 | Award Amount: 8.36M | Year: 2016

Due to an aging population and the spiralling cost of brain disease in Europe and beyond, EDEN2020 aims to develop the gold standard for one-stop diagnosis and minimally invasive treatment in neurosurgery. Supported by a clear business case, it will exploit the unique track record of leading research institutions and key industrial players in the field of surgical robotics to overcome the current technological barriers that stand in the way of real clinical impact. EDEN2020 will provide a step change in the modelling, planning and delivery of diagnostic sensors and therapies to the brain via flexible surgical access, with an initial focus on cancer therapy. It will engineer a family of steerable catheters for chronic disease management that can be robotically deployed and kept in situ for extended periods. The system will feature enhanced autonomy, surgeon cooperation, targeting proficiency and fault tolerance with a suite of technologies that are commensurate to the unique challenges of neurosurgery. Amongst these, the system will be able to sense and perceive intraoperative, continuously deforming, brain anatomy at unmatched accuracy, precision and update rates, and deploy a range of diagnostic optical sensors with the potential to revolutionise todays approach to brain disease management. By modelling and predicting drug diffusion within the brain with unprecedented fidelity, EDEN2020 will contribute to the wider clinical challenge of extending and enhancing the quality of life of cancer patients with the ability to plan therapies around delicate tissue structures and with unparalleled delivery accuracy. EDEN2020 is strengthened by a significant industrial presence, which is embedded within the entire R&D process to enforce best practices and maximise translation and the exploitation of project outputs. As it aspires to impact the state of the art and consolidate the position of European industrial robotics, it will directly support the Europe 2020 Strategy.


The main focus of TreatER is conducting a randomized, placebo-controlled, first-in-human, proof-of-concept, safety and efficacy study of intracerebrally administered CDNF protein therapy in patients with Parkinsons disease (PD), using a neurosurgically implanted Drug Delivery System (DDS), which will also be clinically validated in the study. Thus the TreatER project has two independent goals, either of which alone can have significant impact addressing unmet clinical needs in chronic diseases, and advancing innovative European technologies: 1) Proof-of-concept of CDNF protein therapy for disease modification in PD. The patented European innovation CDNF has further potential in other ER stress related indications. 2) Clinical validation of DDS, an already clinically tested approach for accurately targeted intracerebral infusions in PD. The patented European innovation DDS has also significant potential in other indications needing intracerebral infusions. The clinical study builds on extensive preclinical research and related data on CDNF, including completed acute and chronic toxicology studies in non-human primates supporting an excellent safety profile. Further, the clinical study builds on existing clinical experience on DDS and related neurosurgery. Both conventional and novel means for assessing the efficacy of the treatment will be utilized. This requires strong interdisciplinary expertise and knowledge available in the consortium, including: Regulatory expertise in drug and medical device development; neurological and neurosurgical expertise in PD; PET imaging expertise specific to PD; Scientific expertise in novel neurotrophic factors, in specific CDNF; and GMP manufacturing expertise of novel biological drug compounds. Clinical trial applications are currently being submitted in Finland and Sweden, in accordance with previously obtained scientific advice from regulatory authorities in those countries as well as from MHRA (UK) and EMAs ITF.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 149.97K | Year: 2016

Multi-drug resistant bacteria are a global threat to public health. In order to improve patient management and to provide information for infection control and prevention there is a pressing need for tools that rapidly stratify patients as colonised or infected by drug resistant bacteria in order to minimise the risk of transfer and outbreak. Carbapenemase-producing Enterobacteriaceae (CPE) present an urgent public health risk. These organisms are resistant to the carbapenem class of antibiotics, often considered the “last resort” in the treatment of many bacterial infections. CPEs restrict treatment options and are associated with increased morbidity and mortality. They are readily transmissible in healthcare settings and countries such as Greece and Italy are already considered endemic for some classes of CPE. Public Health England (PHE) guidelines recommend that high risk patients (those previously admitted to hospital within specific geographical areas both inside and outside the UK, or who have been previously identified as CPE-positive) should be immediately isolated from the general patient population upon hospital admission. These patients should undergo screening for CPE, typically via culture on a commercially-produced chromogenic agar designed for isolation of CPE. These tests can take up to 72 hours to produce a result, with testing recommended on days 0, 2 and 4 after admission, meaning that patients can often be isolated for over a week upon admission, in most cases unnecessarily. This project seeks to improve the stratification of the “at risk” cohort of patients by the introduction of a rapid test for the detection of the major carbapenemase gene families. In the UK, 5 carbapenemase gene families account for > 99 % of all carbapenamases found in Enterobacteriaceae referred to as KPC, NDM, IMP, VIM and OXA-48. From a single sample, the test will stratify patients according to the presence or absence of any of the 5 key carbapenemases in a few hours rather than days. Such a test offers the potential to aid earlier diagnosis, facilitating appropriate patient management while allowing prompt deployment of infection prevention and control measures. Phase 1 of the proposed project will focus on the final development of a polymerase chain reaction (PCR) based test for CPE, including testing of simulated samples in collaboration with the Newcastle Freeman hospital. An economic model will also be developed to confirm the cost effectiveness of using a PCR based diagnostic test to identify CPE carriers upon admission to UK hospitals. Phase 2 would address full commercialisation of the product including clinical evaluation towards appropriate regulatory approval, and further clinical utility studies to generate sufficient diagnostic evidence for inclusion within routine testing in healthcare settings.


Apparatus for delivering therapeutic agents to the central nervous system of a subject is described. The apparatus comprises a percutaneous access device (50;140;150;160) having a body (10;52;152) with at least one extracorporeal surface (22;68) and at least one subcutaneous surface. The body (10;52) defines at least one port (12;116) for connection to an implanted intracranial catheter. The port (12;116) is accessible from the extracorporeal surface (22;68) of the device, but is provided with a seal (14;112;142;146) such as a rubber bung between the lumen of the port and the extracorporeal surface (22;68).A guide member (42) is provided that projects from the body (10;52) of the device, the guide member (42) ensuring that the percutaneous access device (50;140;150;160) and an associated delivery unit (34) can only be fitted together one way. The percutaneous access device may have more than two ports (12;116).


This invention concerns a spectroscopic method, apparatus for determining whether a component is present in a sample. In one aspect, the method includes resolving a model of the spectral data separately for candidates from a set of predetermined component reference spectra, and determining whether a component is present in the sample based upon a figure of merit quantifying an effect of including the candidate reference spectrum corresponding to that component in the model.


Patent
Renishaw | Date: 2016-01-27

A non-contact method and apparatus for inspecting an object. At least one first image of the object on which an optical pattern is projected, taken from a first perspective is obtained. At least one second image of the object on which an optical pattern is projected, taken from a second perspective that is different to the first perspective is obtained. At least one common object feature in each of the at least one first and second images is then determined on the basis of an irregularity in the optical pattern as imaged in the at least one first and second images.

Loading Renishaw collaborators
Loading Renishaw collaborators